FDA
-
-
-
-
-
-
-
Simulations Plus responds to FDA draft guidance on streamlined safety studies
-
-
-
-
-
-
-
Simulations Plus (SLP) PT Lowered to $41 at BTIG
-
-
-
-
-
-
-
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
-
-
-
-
-
-
-
Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
-
-
-
-
-
-
-
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
-
-
-
-
-
-
-
Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products
-
-
-
-
-
-
-
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

